Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CLXPFNYSE:OGNNASDAQ:PTCTNASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLXPFCybin$7.35-1.3%$7.47$0.49▼$3.38$1.09BN/A551,962 shs423,747 shsOGNOrganon & Co.$11.11+2.7%$14.32$10.75▼$23.10$2.87B0.732.66 million shs2.93 million shsPTCTPTC Therapeutics$47.39+2.1%$50.22$24.00▼$58.38$3.74B0.58821,653 shs1.04 million shsRAREUltragenyx Pharmaceutical$35.69+2.0%$38.57$29.59▼$60.37$3.35B0.61807,943 shs690,760 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLXPFCybin-3.25%+37.45%-2.61%-16.57%+1,862.59%OGNOrganon & Co.+2.57%-2.80%-29.23%-29.54%-37.84%PTCTPTC Therapeutics+2.11%+17.62%-14.57%+8.10%+88.35%RAREUltragenyx Pharmaceutical+2.03%+7.63%-8.16%-10.78%-19.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLXPFCybinN/AN/AN/AN/AN/AN/AN/AN/AOGNOrganon & Co.4.7919 of 5 stars3.23.03.33.72.51.73.1PTCTPTC Therapeutics3.7599 of 5 stars4.31.00.04.42.60.80.0RAREUltragenyx Pharmaceutical4.5448 of 5 stars4.53.00.03.83.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLXPFCybin 0.00N/AN/AN/AOGNOrganon & Co. 2.43Hold$20.6085.45% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$63.7734.56% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$92.79159.98% UpsideCurrent Analyst Ratings BreakdownLatest CLXPF, PTCT, RARE, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/31/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$78.00 ➝ $75.003/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.003/17/2025RAREUltragenyx PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.003/14/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$72.00 ➝ $78.003/11/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$41.00 ➝ $55.003/7/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$67.00 ➝ $70.003/7/2025PTCTPTC TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$55.002/28/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $72.002/26/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$118.00 ➝ $118.002/18/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $63.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLXPFCybin$680K1,606.17N/AN/A$0.44 per share16.70OGNOrganon & Co.$6.40B0.45$3.56 per share3.12($0.27) per share-41.14PTCTPTC Therapeutics$806.78M4.63$2.28 per share20.80($10.85) per share-4.37RAREUltragenyx Pharmaceutical$560.23M5.98N/AN/A$2.76 per share12.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLXPFCybin-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/AOGNOrganon & Co.$864M$3.333.342.970.9013.49%431.62%8.03%5/1/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$6.34N/AN/AN/A-101.60%-193.80%-38.15%5/1/2025 (Estimated)Latest CLXPF, PTCT, RARE, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025OGNOrganon & Co.$0.92N/AN/AN/A$1.53 billionN/A5/1/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.58N/AN/AN/A$145.98 millionN/A4/24/2025Q1 2025PTCTPTC Therapeutics$0.85N/AN/AN/A$437.16 millionN/A2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billion2/13/2025Q4 2024RAREUltragenyx Pharmaceutical-$1.32-$1.39-$0.07-$1.39$163.23 million$164.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLXPFCybinN/AN/AN/AN/AN/AOGNOrganon & Co.$1.1210.08%+25.99%33.63%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ALatest CLXPF, PTCT, RARE, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLXPFCybinN/A13.5713.57OGNOrganon & Co.17.731.701.21PTCTPTC TherapeuticsN/A2.102.04RAREUltragenyx PharmaceuticalN/A2.372.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLXPFCybin0.01%OGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipCLXPFCybinN/AOGNOrganon & Co.1.40%PTCTPTC Therapeutics5.50%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLXPFCybin50148.60 millionN/ANot OptionableOGNOrganon & Co.10,000257.95 million253.93 millionNot OptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableRAREUltragenyx Pharmaceutical1,31093.89 million86.99 millionOptionableCLXPF, PTCT, RARE, and OGN HeadlinesRecent News About These CompaniesHow did Emil Kakkis build Ultragenyx into an ultra-rare disease powerhouse?April 17 at 9:15 PM | bizjournals.comUltragenyx: Commercial Engine Fuels Rare Disease PipelineApril 16 at 10:10 AM | seekingalpha.comInvesco Ltd. Grows Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 16 at 4:06 AM | marketbeat.comGranite Investment Partners LLC Cuts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 15 at 7:40 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Geode Capital Management LLCApril 15 at 4:20 AM | marketbeat.comUltragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 14, 2025 | msn.comF M Investments LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 14, 2025 | marketbeat.comWhich Is a Better Investment, Alvotech or Ultragenyx Pharmaceutical Inc. Stock?April 11, 2025 | aaii.comUltragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?April 10, 2025 | zacks.comUltragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 52-Week Low - Should You Sell?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Invests $337,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 9, 2025 | marketbeat.comFederated Hermes Inc. Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 9, 2025 | marketbeat.comFranklin Resources Inc. Purchases 208,456 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 9, 2025 | marketbeat.comCalifornia Public Employees Retirement System Purchases 17,225 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 9, 2025 | marketbeat.comExodusPoint Capital Management LP Purchases Shares of 87,017 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 8, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Trims Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 8, 2025 | marketbeat.comBryce Point Capital LLC Invests $451,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 7, 2025 | marketbeat.comTrexquant Investment LP Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 7, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stake Lessened by B. Metzler seel. Sohn & Co. AGApril 7, 2025 | marketbeat.com961,794 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Norges BankApril 7, 2025 | marketbeat.comMotley Fool Asset Management LLC Has $2.04 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)April 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military Spending5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatEverything About Amazon Stock Signals a Buy—Time to Load Up?By Sam Quirke | March 20, 2025View Everything About Amazon Stock Signals a Buy—Time to Load Up?CLXPF, PTCT, RARE, and OGN Company DescriptionsCybin OTCMKTS:CLXPF$7.35 -0.10 (-1.34%) As of 04/17/2025Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.Organon & Co. NYSE:OGN$11.11 +0.29 (+2.66%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$11.06 -0.05 (-0.43%) As of 04/17/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$47.39 +0.98 (+2.11%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$47.42 +0.02 (+0.05%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Ultragenyx Pharmaceutical NASDAQ:RARE$35.69 +0.71 (+2.03%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$36.12 +0.43 (+1.19%) As of 04/17/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
